Keros Therapeutics (NASDAQ:KROS) Earns “Neutral” Rating from Guggenheim

Keros Therapeutics (NASDAQ:KROS)‘s stock had its “neutral” rating reiterated by investment analysts at Guggenheim in a report issued on Friday,Benzinga reports.

Several other equities research analysts have also recently issued reports on KROS. BTIG Research cut Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. Scotiabank reduced their price objective on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a report on Thursday. Jefferies Financial Group began coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating for the company. William Blair downgraded shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 12th. Finally, Oppenheimer dropped their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a report on Thursday. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $52.56.

Keros Therapeutics Trading Up 3.2 %

Shares of KROS opened at $10.86 on Friday. Keros Therapeutics has a 12-month low of $9.77 and a 12-month high of $73.00. The firm has a market capitalization of $439.94 million, a P/E ratio of -2.08 and a beta of 1.43. The firm has a 50-day moving average price of $36.37 and a 200 day moving average price of $47.13.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Keros Therapeutics’s revenue for the quarter was up 4750.0% on a year-over-year basis. During the same period last year, the business posted ($1.33) earnings per share. Equities research analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Institutional Trading of Keros Therapeutics

Several hedge funds have recently modified their holdings of the stock. Point72 Asset Management L.P. grew its stake in Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after purchasing an additional 577,220 shares in the last quarter. Alkeon Capital Management LLC boosted its stake in shares of Keros Therapeutics by 18.7% in the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after buying an additional 298,694 shares during the period. Parkman Healthcare Partners LLC grew its position in shares of Keros Therapeutics by 112.3% during the third quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company’s stock worth $24,493,000 after buying an additional 223,155 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in shares of Keros Therapeutics by 814.6% during the third quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock worth $12,990,000 after buying an additional 199,245 shares during the period. Finally, FMR LLC raised its holdings in Keros Therapeutics by 3.8% in the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after acquiring an additional 179,374 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.